Pasithea Therapeutics (KTTA) Restructuring Costs (2022 - 2025)

Pasithea Therapeutics (KTTA) posted Restructuring Costs of $45.0 for Q2 2025, down 93.13% sequentially from $655.0 in Q1 2025.

Pasithea Therapeutics (KTTA) Restructuring Costs (2022 - 2025) Analysis & Trends

Pasithea Therapeutics has reported Restructuring Costs for 2 years, with the latest figure at $45.0 in Q2 2025.

Quarterly Restructuring Costs changed N/A year-over-year to $45.0 in Q2 2025, while the trailing twelve-month figure through Dec 2025 was $700.0 (changed N/A YoY) and the FY2025 annual result came in at $700.0, changed N/A from the prior year.
Restructuring Costs declined to $45.0 in Q2 2025 per KTTA's latest filing, from $655.0 in the prior quarter.
Over five years, Restructuring Costs peaked at $326380.0 in Q1 2022 and troughed at $45.0 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Pasithea Therapeutics	15.13 Mn	15.13 Mn	-

Download Data